| Literature DB >> 30829084 |
Cai Yi Wang1, Sunggun Lee1, Hyun-Jae Jang2, Xiang Dong Su1, Heng-Shan Wang3, Young Ho Kim1, Seo Young Yang1.
Abstract
The aerial parts of Tetrastigma hemsleyanum (APTH) have been used as a functional tea in China. The purpose of the current study was to identify the bioactive constituents with inhibitory activity against soluble epoxide hydrolase (sEH) and inducible nitric oxide synthase (iNOS), which are jointly considered potential therapeutic targets for vascular system diseases. In the present study, 39 compounds (1-39) were isolated from the APTH. Among them, compounds 8, 10, 12, 16, 17, 19, and 32 displayed potential activities, with IC50 values ranging from 4.5 to 9.5 µM, respectively, and all in non-competitive inhibition mode. Compounds 5, 10, 12, 19, and 32 displayed potent iNOS inhibitory effects, with IC50 values ranging from 15.6 to 47.3 µM. The results obtained in this work contribute to a better understanding of the pharmacological activities of T. hemsleyanum and its potential application as a functional food.Entities:
Keywords: nitric oxide synthase; phenolics; soluble epoxide hydrolase; vitaceae
Mesh:
Substances:
Year: 2019 PMID: 30829084 PMCID: PMC6407587 DOI: 10.1080/14756366.2019.1584621
Source DB: PubMed Journal: J Enzyme Inhib Med Chem ISSN: 1475-6366 Impact factor: 5.051
Figure 1.Chemical structures of isolated compounds (1–39) from T. hemsleyanum (Glc: glucosyl; Rha: Rhamnosyl. The configurations of all the sugar residues in the glycosides were determined as β-D with 1H NMR).
Figure 2.Isolation process diagram of compounds (1–39) from T. hemsleyanum.
Inhibition and IC50 values of compounds (1–39) on sEHa.
| Compounds | 100 µM (%) | IC50 (µM) | Type (Ki, µM) | Compounds | 100 µM (%) | IC50 (µM) | Type (Ki, µM) |
|---|---|---|---|---|---|---|---|
| 74.3 ± 3.4 | 41.9 ± 1.2 | N.T | N.I | N.T | N.T | ||
| 4.4 ± 3.2 | N.T | N.T | 31.9 ± 4.5 | N.T | N.T | ||
| 67.1 ± 3.4 | 60.7 ± 1.9 | N.T | 10.7 ± 3.0 | N.T | N.T | ||
| 68.3 ± 3.4 | 30.4 ± 0.8 | N.T | 38.6 ± 0.2 | N.T | N.T | ||
| 77.7 ± 2.6 | 33.1 ± 0.3 | N.T | 42.0 ± 3.9 | N.T | N.T | ||
| 111.1 ± 1.9 | 14.7 ± 0.4 | N.T | 21.3 ± 0.2 | N.T | N.T | ||
| 69.2 ± 0.9 | 50.8 ± 1.5 | N.T | 17.5 ± 0.2 | N.T | N.T | ||
| 165.3 ± 3.5 | 9.4 ± 0.2 | Mixed (13.7 ± 0.2) | 22.1 ± 0.9 | N.T | N.T | ||
| 32.3 ± 2.7 | N.T | N.T | 39.7 ± 4.4 | N.T | N.T | ||
| 58.0 ± 2.0 | 6.8 ± 2.4 | Non-competitive (18.6 ± 0.9) | 149.1 ± 4.7 | 21.0 ± 0.4 | N.T | ||
| 34.5 ± 2.5 | N.T | N.T | 43.0 ± 1.1 | N.T | N.T | ||
| 92.4 ± 2.0 | 7.2 ± 0.3 | Non-competitive (24.4 ± 0.7) | 154.9 ± 1.7 | 6.8 ± 0.9 | N.T | ||
| 22.7 ± 3.9 | N.T | N.T | 19.4 ± 0.8 | N.T | N.T | ||
| 78.0 ± 1.0 | 21.3 ± 0.3 | N.T | 13.3 ± 0.2 | N.T | N.T | ||
| 60.2 ± 0.5 | 18.3 ± 0.2 | N.T | 10.5 ± 3.0 | N.T | N.T | ||
| 95.2 ± 0.2 | 6.2 ± 0.1 | N.T | N.I | N.T | N.T | ||
| 83.8 ± 3.7 | 9.5 ± 0.1 | N.T | 24.6 ± 3.1 | N.T | N.T | ||
| 52.3 ± 2.6 | N.T | N.T | 39.5 ± 4.1 | N.T | N.T | ||
| >100 | 4.5 ± 0.2 | Mixed (10.2 ± 0.2) | N.I | N.T | N.T | ||
| N.I | N.T | N.T | |||||
| 13.3 ± 0.8 | N.T | 13.3 ± 0.8 |
N.T: Not Tested; N.I: Not Inhibition.
aCompounds were tested three times.
bAUDA was the positive control.
Figure 3.Study of binding mechanism between compounds 8, 10, 12, 19 and sEH: Dixon plots for compounds 8 (A), 10 (B), 12 (C) and 19 (D), respectively. Lineweaver–Burk plots for compounds 8 (E), 10 (F), 12 (G) and 19 (H), respectively. Data are the mean of three experiments carried out in triplicate and were determined by one-way analysis of variance followed by Dunnett’s multiple comparison test, p < .05 versus control.
Inhibition of NO production in macrophage RAW264.7 cells by compounds 1–39 a.
| Compounds | 50 µM(%) | IC50 (µM) | Compounds | 50 µM(%) | IC50 (µM) |
|---|---|---|---|---|---|
| 5.7 | N.T | 16.2 | N.T | ||
| 19.7 | N.T | 18.3 | N.T | ||
| 26.1 | N.T | 14.1 | N.T | ||
| N.I | N.T | 22.2 | N.T | ||
| 53.0 | 45.3 ± 1.4 | 17.0 | N.T | ||
| 1.8 | N.T | 11.4 | N.T | ||
| 10.7 | N.T | 24.0 | N.T | ||
| 25.2 | N.T | 6.2 | N.T | ||
| N.I | N.T | 13.4 | N.T | ||
| 93.0 | 15.6 ± 1.6 | 21.5 | N.T | ||
| 10.8 | N.T | 10.6 | N.T | ||
| 98.9 | 12.2 ± 0.1 | 77.7 | 30.6 ± 1.8 | ||
| N.I | N.T | 3.0 | N.T | ||
| 9.0 | N.T | 12.8 | N.T | ||
| 3.0 | N.T | 15.9 | N.T | ||
| 26.2 | N.T | 20.9 | N.T | ||
| 29.9 | N.T | 14.5 | N.T | ||
| 32.1 | N.T | 8.9 | N.T | ||
| 50.1 | 47.3 ± 6.9 | 20.3 | N.T | ||
| 13.9 | N.T | ||||
| 10.5 ± 0.1 | 10.5 ± 0.1 |
N.T: Not Tested; N.I: Not Inhibition.
aData were shown as IC50 values (means ± SE) of experiments performed in triplicate (n = 3).
TH extracts were exhibited IC50 concentration at 22.69 ± 0.75 µM.
bDexametasone was used as the positive control.
Figure 4.The binding model of compounds 10 and 12 in complex with sEH and iNOS. (a) The proposed binding mode and interaction of molecular modelling between sEH and A/S38_601, compounds 10 and 12. (b) The proposed binding mode and interaction of molecular modelling between iNOS and AT2_1906, compounds 10 and 12. The compounds and important amino acids in the binding pockets are shown in stick model, whereas sEH is depicted in the ribbon model.